Express Pharma
NOVEMBER 7, 2023
The type 2 diabetes (T2D) landscape has historically been dominated by insulin receptor (IR) targeting drugs. This condition disrupts glucose metabolism, resulting in high blood glucose levels and a variety of effects thereafter, such as an increased risk of stroke and diabetic neuropathy. IR’s role in T2D is well-defined.
Express Pharma
APRIL 12, 2024
These were further analysed and shortlisted to ensure that there is entrepreneurial, scientific, innovation and investment capability on ground to see these succeed in the run up to the next general elections by 2029. per cent increase in happiness; 0.27 years of additional life expectancy; a decrease of 0.72
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
NOVEMBER 12, 2023
In March 2022, desidustat was approved in India to treat anemia associated with chronic kidney disease (CKD), whereas saroglitazor was approved in June 2013 for diabetic dyslipidemia and hypertriglyceridemia. million cases in 2029, equating to an annual growth rate of 6.46 million cases in 2023 to 12.6 million cases in 2023 to 6.5
European Pharmaceutical Review
JUNE 26, 2024
[the new facility will double] the combined square footage of all three of [Novo Nordisk]’s existing facilities in North Carolina” Overall, the expansion will support Novo Nordisk’s ability to produce injectable treatments for obesity and other chronic diseases such as diabetes. Completion is expected between 2027 and 2029.
European Pharmaceutical Review
NOVEMBER 10, 2023
The construction projects will be finalised from the end of 2025 through to 2029. Novo Nordisk’s Denmark manufacturing facilities Currently, Novo Nordisk’s Kalundborg production facilities manufacture products for treating obesity and diabetes as well as several biopharmaceutical products, employing around 4,400 employees.
Pharmaceutical Technology
APRIL 28, 2023
Originally granted approval in its largest market, the US, in 2017, Ozempic has subsequently obtained approval for three distinct dosages, 0.5mg, 1.0mg, and 2.0mg, for the treatment of type 2 diabetes. It is forecast that Ozempic will sustain its sales growth over the next five years, with an expected annual sales figure of $17bn in 2029.
pharmaphorum
SEPTEMBER 30, 2022
Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition for years, and a new judgment looks set to protect its third biggest-selling drug for another few years. 8,414,921), which covers the co-formulation of sitagliptin and metformin and is due to expire in 2029.
Expert insights. Personalized for you.
111 
Let's personalize your content